id	report_number	mvb_report_number	data_provider	data_title	data_source	data_source_type	data_date	sample_source	sample_info	infection_history	vac_history	vac_boost	vac_boost_dose	vac_boost_dose_unit	boost_info	boost_glossid	vac_mvbid	boost_class	experiment_id	assay_cat	assay_type	assay_type_mod	viral_name	viral_lineage	viral_sublineage	viral_mutation	vaccine_activity	vaccine_activity_unit	vaccine_activity_description	boost1_time_unit	boost1_time0	boost1_activity0	boost1_time1	boost1_time1_info	boost1_activity1	boost1_activitiy1_norm	boost1_effect1	boost1_time2	boost1_time2_info	boost1_activity2	boost1_activity2_norm	boost1_effect2	boost1_time3	boost1_time3_info	boost1_activity3	boost1_activity3_norm	boost1_effect3	database_name	group_name	eb_group_number
4187		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster			29		1782.7		1.00	181		617.2		1.00					
4188		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster			29		2278		1.28	181		1040		1.69					
4189		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster			29		825.6		1.00	181		125.2		1.00					
4190		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster			29		1095.3		1.33	181		343.5		2.74					
4191		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster			29		630.5		1.00	181		145.6		1.00					
4192		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster			29		1389.8		2.20	181		312.9		2.15					
4193		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster			29		844.1		1.00	181		408		1.00					
4194		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster			29		1481.2		1.75	181		491.3		1.20					
4195		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	150	29		1952	13.01	1.00	181		673	4.49	1.00					
4196		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	103	29		2172	21.09	1.62	181		1006	9.77	2.18					
4197		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	100	?g		None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	100	29		4503	45.03	3.46	181		1483	14.83	3.30					
4198		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	38	29		921	24.24	1.00	181		139	3.66	1.00					
4199		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	26	29		1032	39.69	1.64	181		326	12.54	3.43					
4200		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	100	?g		None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	24	29		1642	68.42	2.82	181		414	17.25	4.71					
4201		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster	0	38	29		629	16.55	1.00	181		146	3.84	1.00					
4202		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster	0	39	29		1408	36.10	2.18	181		317	8.13	2.12					
4203		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster	0	47	29		828	17.62	1.00	181		397	8.45	1.00					
4204		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster	0	53	29		1507	28.43	1.61	181		499	9.42	1.11					
4205		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	3	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Spike binding antibody titer gm	AU/mL		days post booster	0	40948	29		480711	11.74	1.00										
4727																None	None																														
4206		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	3	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Spike binding antibody titer gm	AU/mL		days post booster	0	26992	29		592403	21.95	1.87										
4207		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	100	?g		None	None	Bivalent	3	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Spike binding antibody titer gm	AU/mL		days post booster	0	17207	29		803379	46.69	3.98										
4208		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	3	Binding	Meso Scale Discovery assay		gamma	P.1	P.1		Spike binding antibody titer gm	AU/mL		days post booster	0	18391	29		231094	12.57	1.00										
4209		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	3	Binding	Meso Scale Discovery assay		gamma	P.1	P.1		Spike binding antibody titer gm	AU/mL		days post booster	0	12674	29		313177	24.71	1.97										
4210		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	100	?g		None	None	Bivalent	3	Binding	Meso Scale Discovery assay		gamma	P.1	P.1		Spike binding antibody titer gm	AU/mL		days post booster	0	8108	29		406226	50.10	3.99										
4211		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	3	Binding	Meso Scale Discovery assay		alpha	B.1.1.7	B.1.1.7		Spike binding antibody titer gm	AU/mL		days post booster	0	25644	29		368165	14.36	1.00										
4212		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	3	Binding	Meso Scale Discovery assay		alpha	B.1.1.7	B.1.1.7		Spike binding antibody titer gm	AU/mL		days post booster	0	17040	29		454210	26.66	1.86										
4213		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	100	?g		None	None	Bivalent	3	Binding	Meso Scale Discovery assay		alpha	B.1.1.7	B.1.1.7		Spike binding antibody titer gm	AU/mL		days post booster	0	11040	29		603467	54.66	3.81										
4214		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	3	Binding	Meso Scale Discovery assay		beta	B.1.351	B.1.351		Spike binding antibody titer gm	AU/mL		days post booster	0	14524	29		199067	13.71	1.00										
4215		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	50	?g		None	None	Bivalent	3	Binding	Meso Scale Discovery assay		beta	B.1.351	B.1.351		Spike binding antibody titer gm	AU/mL		days post booster	0	10216	29		299241	29.29	2.14										
4216		1	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human			2 x mRNA-1273	mRNA-1273.211	100	?g		None	None	Bivalent	3	Binding	Meso Scale Discovery assay		beta	B.1.351	B.1.351		Spike binding antibody titer gm	AU/mL		days post booster	0	6628	29		393776	59.41	4.33										
4217		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	1521	28		5649.3	3.71	1.00										
4218		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273.214	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	1266.7	28		5977.3	4.72	1.27										
4219		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	332	28		1473.5	4.44	1.00										
4220		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273.214	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	298.1	28		2372.4	7.96	1.79										
4221		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	140	28		492	3.51	1.00										
4222		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273.214	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	116	28		727	6.27	1.78										
4223		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Anti-spike IgG GM	AU/mL		days post booster	0	299028	28		753438	2.52	1.00										
4224		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Anti-spike IgG GM	AU/mL		days post booster	0	282635	28		856394	3.03	1.20										
4728																None	None																														
4729																None	None																														
4730																None	None																														
4225		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		Omicron	B.1.1.529	BA.1		Anti-spike IgG GM	AU/mL		days post booster	0	58640	28		163486	2.79	1.00										
4226		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		Omicron	B.1.1.529	BA.1		Anti-spike IgG GM	AU/mL		days post booster	0	54956	28		201367	3.66	1.31										
4227		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		beta	B.1.351	B.1.351		Anti-spike IgG GM	AU/mL		days post booster	0	135259	28		352739	2.61	1.00										
4228		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		beta	B.1.351	B.1.351		Anti-spike IgG GM	AU/mL		days post booster	0	127083	28		403166	3.17	1.22										
4229		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		delta	B.1.617.2	B.1.617.2		Anti-spike IgG GM	AU/mL		days post booster	0	193939	28		502005	2.59	1.00										
4230		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		delta	B.1.617.2	B.1.617.2		Anti-spike IgG GM	AU/mL		days post booster	0	181213	28		546450	3.02	1.16										
4231		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		gamma	P.1	P.1		Anti-spike IgG GM	AU/mL		days post booster	0	150030	28		384401	2.56	1.00										
4232		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		gamma	P.1	P.1		Anti-spike IgG GM	AU/mL		days post booster	0	138574	28		441810	3.19	1.24										
4233		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		alpha	B.1.1.7	B.1.1.7		Anti-spike IgG GM	AU/mL		days post booster	0	223595	28		568576	2.54	1.00										
4234		2	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human			3 x mRNA-1273	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		alpha	B.1.1.7	B.1.1.7		Anti-spike IgG GM	AU/mL		days post booster	0	207587	28		652098	3.14	1.24										
4235		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster					12054		1.00										
4236		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster					8488		0.70										
4237		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster					2340		1.00										
4238		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster					2133		0.91										
4239		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		ID50 GMT			days post booster					2956		1.00										
4240		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		ID50 GMT			days post booster					2534		0.86										
4241		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster					1366		1.00										
4242		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster					1649		1.21										
4243		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4.6		ID50 GMT			days post booster					1003		1.00										
4731																None	None																														
4244		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4.6		ID50 GMT			days post booster					1142		1.14										
4245		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.75		ID50 GMT			days post booster					1628		1.00										
4246		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.75		ID50 GMT			days post booster					1385		0.85										
4247		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.75.2		ID50 GMT			days post booster					274		1.00										
4248		3	Columbia University Vagelos College of Physicians and Surgeons	Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot	https://doi.org/10.1101/2022.10.22.513349	Pre-print	10/24/2022	human			3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.75.2		ID50 GMT			days post booster					354		1.29										
4249		4	Pfizer	Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine	https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron	Press release	11/04/2022	human	Over 55 years of age	Mixed	3 x uspecified vaccine	BNT162b2				None	None	Monovalent	1	Neutralization			Omicron	B.1.1.529	BA.4/5		NT50 GMT			days post booster			30			2.90	1.00										
4250		4	Pfizer	Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine	https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron	Press release	11/04/2022	human	18-55 years of age	Mixed	3 x uspecified vaccine	BNT162b2				None	None	Monovalent	1	Neutralization			Omicron	B.1.1.529	BA.4/5		NT50 GMT			days post booster			30			9.50											
4251		4	Pfizer	Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine	https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron	Press release	11/04/2022	human	Over 55 years of age	Mixed	3 x uspecified vaccine	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization			Omicron	B.1.1.529	BA.4/5		NT50 GMT			days post booster			30			13.20	4.55										
4252		5	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice			2 x BNT162b2	BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		pVNT50 GMT			days post booster					9870		1.00										
4253		5	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice			2 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		pVNT50 GMT			days post booster					5869		0.59										
4254		5	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice			2 x BNT162b2	BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		pVNT50 GMT			days post booster					2075		1.00										
4255		5	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice			2 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		pVNT50 GMT			days post booster					2075		1.00										
4256		5	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice			2 x BNT162b2	BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		pVNT50 GMT			days post booster					872		1.00										
4257		5	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice			2 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		pVNT50 GMT			days post booster					2691		3.09										
4258		5	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice			2 x BNT162b2	BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		pVNT50 GMT			days post booster					951		1.00										
4259		5	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice			2 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		pVNT50 GMT			days post booster					3200		3.36										
4260		5	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice			2 x BNT162b2	BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		pVNT50 GMT			days post booster					800		1.00										
4732																None	None																														
4733																None	None																														
4734																None	None																														
4261		5	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice			2 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		pVNT50 GMT			days post booster					2075		2.59										
4262		6	Pfizer	PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5) Fact sheet	https://www.fda.gov/media/161327/download	FDA fact sheet	10/12/2022	human	Over 55 years of age		3 x BNT162b2	BNT162b2				None	None	Monovalent	1	Neutralization	Live virus replication assay	CPE	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 GMT			days post booster			30		5998.1		1.00										
4263		6	Pfizer	PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5) Fact sheet	https://www.fda.gov/media/161327/download	FDA fact sheet	10/12/2022	human	Over 55 years of age		3 x BNT162b2	Bivalent BNT162b2 OMI(BA.1)				None	None	Bivalent	1	Neutralization	Live virus replication assay	CPE	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 GMT			days post booster			30		5933.2		0.99										
4264		6	Pfizer	PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5) Fact sheet	https://www.fda.gov/media/161327/download	FDA fact sheet	10/12/2022	human	Over 55 years of age		3 x BNT162b2	BNT162b2				None	None	Monovalent	1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		NT50 GMT			days post booster			30		455.8		1.00										
4265		6	Pfizer	PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5) Fact sheet	https://www.fda.gov/media/161327/download	FDA fact sheet	10/12/2022	human	Over 55 years of age		3 x BNT162b2	Bivalent BNT162b2 OMI(BA.1)				None	None	Bivalent	1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		NT50 GMT			days post booster			30		711		1.56										
4266		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		FFRNT50 GMT			months post booster			1-3		1533		1.00										
4267		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		FFRNT50 GMT			months post booster			1		3620		2.36										
4268		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Infected	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		FFRNT50 GMT			months post booster			1		5776												
4269		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4/5		FFRNT50 GMT			months post booster			1-3		95		1.00										
4270		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4/5		FFRNT50 GMT			months post booster			1		298		3.14										
4271		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Infected	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4/5		FFRNT50 GMT			months post booster			1		1558												
4272		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BF.7		FFRNT50 GMT			months post booster			1-3		69		1.00										
4273		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BF.7		FFRNT50 GMT			months post booster			1		305		4.42										
4274		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Infected	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BF.7		FFRNT50 GMT			months post booster			1		1223												
4275		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4.6		FFRNT50 GMT			months post booster			1-3		62		1.00										
4276		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4.6		FFRNT50 GMT			months post booster			1		183		2.95										
4348		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	5	Binding	ECLA		Omicron	B.1.1.529	BA.1		Relative Light Unit								815		0.82										
4277		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Infected	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4.6		FFRNT50 GMT			months post booster			1		744												
4278		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.2.75.2		FFRNT50 GMT			months post booster			1-3		26		1.00										
4279		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.2.75.2		FFRNT50 GMT			months post booster			1		98		3.77										
4280		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Infected	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.2.75.2		FFRNT50 GMT			months post booster			1		367												
4281		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BQ.1.1		FFRNT50 GMT			months post booster			1-3		22		1.00										
4282		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BQ.1.1		FFRNT50 GMT			months post booster			1		73		3.32										
4283		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Infected	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BQ.1.1		FFRNT50 GMT			months post booster			1		267												
4284		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	XBB.1		FFRNT50 GMT			months post booster			1-3		15		1.00										
4285		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	XBB.1		FFRNT50 GMT			months post booster			1		35		2.33										
4286		7	University of Texas Medical Branch	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster	https://doi.org/10.1101/2022.10.31.514580	Pre-print	11/04/2022	human		Infected	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	XBB.1		FFRNT50 GMT			months post booster			1		103												
4287		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	2313			16976	7.34	1.00										
4288		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.351+mRNA-1273.529				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	2854			16115	5.65	0.77										
4289		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.617.2+mRNA-1273.529				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	2773			21972	7.92	1.08										
4290		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.214				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	2598			21096	8.12	1.11										
4291		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster	0	1138			9327	8.20	1.00										
4292		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.351+mRNA-1273.529				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster	0	1313			9807	7.47	0.91										
4694																None	None																														
4293		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.617.2+mRNA-1273.529				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster	0	1379			12773	9.26	1.13										
4294		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.214				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster	0	1292			10798	8.36	1.02										
4295		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	550			5982	10.88	1.00										
4296		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.351+mRNA-1273.529				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	678			9603	14.16	1.30										
4297		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.617.2+mRNA-1273.529				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	659			8608	13.06	1.20										
4298		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.214				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	651			7814	12.00	1.10										
4299		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster	0	170			1997	11.75	1.00										
4300		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.351+mRNA-1273.529				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster	0	195			3724	19.10	1.63										
4301		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.617.2+mRNA-1273.529				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster	0	208			3808	18.31	1.56										
4302		8	National Institute of Allergy and Infectious Diseases	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses	https://doi.org/10.1101/2022.07.12.22277336	Pre-print	07/15/2022	human		Naïve	Primed and single boosted wtih approved or EUA vaccines	mRNA-1273.214				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster	0	230			3747	16.29	1.39										
4303		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 GMT			days post booster	0	5197			21507	4.14	1.00										
4304		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 GMT			days post booster	0	4188			31759	7.58	2.02										
4305		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 GMT			days post booster	0	3186			50955	15.99	4.26										
4306		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 GMT			days post booster	0	3633			40575	11.17	2.98										
4307		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		NT50 GMT			days post booster	0	307			3224	10.50	1.00										
4308		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		NT50 GMT			days post booster	0	155			3170	20.45	1.95										
4309		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		NT50 GMT			days post booster	0	235			4875	20.74	1.98										
4695																None	None																														
4696																None	None																														
4697																None	None																														
4310		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		NT50 GMT			days post booster	0	214			3315	15.49	1.48										
4311		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		NT50 GMT			days post booster	0	345			2590	7.51	1.00										
4312		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		NT50 GMT			days post booster	0	277			4029	14.55	1.94										
4313		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		NT50 GMT			days post booster	0	336			5196	15.46	2.06										
4314		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		NT50 GMT			days post booster	0	277			4938	17.83	2.37										
4315		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		NT50 GMT			days post booster	0	184			2829	15.38	1.00										
4316		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		NT50 GMT			days post booster	0	212			3929	18.53	1.21										
4317		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		NT50 GMT			days post booster	0	86			3693	42.94	2.79										
4318		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		NT50 GMT			days post booster	0	212			3693	17.42	1.13										
4319		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	2	Cellular response	T cell	Intracellular cytokine staining assay	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		% IFN+/CD8+ T Cells			days post booster	0	0.044			0.04	0.91	1.00										
4320		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	2	Cellular response	T cell	Intracellular cytokine staining assay	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		% IFN+/CD8+ T Cells			days post booster	0	0.049			0.078	1.59	1.75										
4321		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	2	Cellular response	T cell	Intracellular cytokine staining assay	Omicron	B.1.1.529	BA.1		% IFN+/CD8+ T Cells			days post booster	0	0.027			0.06	2.22	1.00										
4322		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	2	Cellular response	T cell	Intracellular cytokine staining assay	Omicron	B.1.1.529	BA.1		% IFN+/CD8+ T Cells			days post booster	0	0.024			0.062	2.58	1.16										
4323		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	2	Cellular response	T cell	Intracellular cytokine staining assay	Omicron	B.1.1.529	BA.5		% IFN+/CD8+ T Cells			days post booster	0	0.027			0.048	1.78	1.00										
4324		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	2	Cellular response	T cell	Intracellular cytokine staining assay	Omicron	B.1.1.529	BA.5		% IFN+/CD8+ T Cells			days post booster	0	0.024			0.046	1.92	1.08										
4325		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	3	Cellular response	T cell	Intracellular cytokine staining assay	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		% IFN+/CD4+ T Cells			days post booster	0	0.056			0.16	2.86	1.00										
4326		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	3	Cellular response	T cell	Intracellular cytokine staining assay	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		% IFN+/CD4+ T Cells			days post booster	0	0.065			0.1	1.54	0.54										
4327		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	3	Cellular response	T cell	Intracellular cytokine staining assay	Omicron	B.1.1.529	BA.1		% IFN+/CD4+ T Cells			days post booster	0	0.048			0.073	1.52	1.00										
4328		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	3	Cellular response	T cell	Intracellular cytokine staining assay	Omicron	B.1.1.529	BA.1		% IFN+/CD4+ T Cells			days post booster	0	0.052			0.087	1.67	1.10										
4329		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	3	Cellular response	T cell	Intracellular cytokine staining assay	Omicron	B.1.1.529	BA.5		% IFN+/CD4+ T Cells			days post booster	0	0.06			0.13	2.17	1.00										
4330		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	3	Cellular response	T cell	Intracellular cytokine staining assay	Omicron	B.1.1.529	BA.5		% IFN+/CD4+ T Cells			days post booster	0	0.051			0.072	1.41	0.65										
4331		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	4	Binding	ELISA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		ELISA Titer								41015		1.00										
4332		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	4	Binding	ELISA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		ELISA Titer								40819		1.00										
4333		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	4	Binding	ELISA		delta	B.1.617.2	B.1.617.2		ELISA Titer								35512		1.00										
4334		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	4	Binding	ELISA		delta	B.1.617.2	B.1.617.2		ELISA Titer								31034		0.87										
4335		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	4	Binding	ELISA		Omicron	B.1.1.529	BA.1		ELISA Titer								5762		1.00										
4336		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	4	Binding	ELISA		Omicron	B.1.1.529	BA.1		ELISA Titer								3435		0.60										
4337		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	4	Binding	ELISA		Omicron	B.1.1.529	BA.2		ELISA Titer								3930		1.00										
4338		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	4	Binding	ELISA		Omicron	B.1.1.529	BA.2		ELISA Titer								2895		0.74										
4339		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	4	Binding	ELISA		Omicron	B.1.1.529	BA.5		ELISA Titer								3951		1.00										
4340		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	4	Binding	ELISA		Omicron	B.1.1.529	BA.5		ELISA Titer								4664		1.18										
4341		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	5	Binding	ECLA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		Relative Light Unit								4563		1.00										
4342		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	5	Binding	ECLA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		Relative Light Unit								4929		1.08										
4343		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	5	Binding	ECLA		beta	B.1.351	B.1.351		Relative Light Unit								1921		1.00										
4344		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	5	Binding	ECLA		beta	B.1.351	B.1.351		Relative Light Unit								2036		1.06										
4345		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	5	Binding	ECLA		delta	B.1.617.2	B.1.617.2		Relative Light Unit								2330		1.00										
4346		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	5	Binding	ECLA		delta	B.1.617.2	B.1.617.2		Relative Light Unit								2490		1.07										
4347		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	5	Binding	ECLA		Omicron	B.1.1.529	BA.1		Relative Light Unit								998		1.00										
4698																None	None																														
4349		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	5	Binding	ECLA		Omicron	B.1.1.529	BA.2		Relative Light Unit								1177		1.00										
4350		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	5	Binding	ECLA		Omicron	B.1.1.529	BA.2		Relative Light Unit								1300		1.10										
4351		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	5	Binding	ECLA		Omicron	B.1.1.529	BA.5		Relative Light Unit								1106		1.00										
4352		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	5	Binding	ECLA		Omicron	B.1.1.529	BA.5		Relative Light Unit								1647		1.49										
4353		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	6	Cellular response	B cell	Flow cytometry	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		%RBD+/Memory B Cells								0.051		1.00										
4354		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	6	Cellular response	B cell	Flow cytometry	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		%RBD+/Memory B Cells								0.064		1.25										
4355		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	6	Cellular response	B cell	Flow cytometry	Omicron	B.1.1.529	BA.5		%RBD+/Memory B Cells								0.079		1.00										
4356		9	Beth Israel Deaconess Medical Center	Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters	https://doi.org/10.1056/NEJMc2213948	Peer-reviewed publication	02/09/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	6	Cellular response	B cell	Flow cytometry	Omicron	B.1.1.529	BA.5		%RBD+/Memory B Cells								0.091		1.15										
4357		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 GMT			days post booster	0	5197			21507	4.14	1.00										
4358		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 GMT			days post booster	0	3633			40515	11.15	2.69										
4359		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		NT50 GMT			days post booster	0	184			2829	15.38	1.00										
4360		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		NT50 GMT			days post booster	0	212			3693	17.42	1.13										
4361		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BF.7		NT50 GMT			days post booster	0	167			2276	13.63	1.00										
4362		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BF.7		NT50 GMT			days post booster	0	131			2399	18.31	1.34										
4363		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.75.2		NT50 GMT			days post booster	0	117			745	6.37	1.00										
4364		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.75.2		NT50 GMT			days post booster	0	33			883	26.76	4.20										
4365		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BQ.1.1		NT50 GMT			days post booster	0	49			406	8.29	1.00										
4366		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BQ.1.1		NT50 GMT			days post booster	0	45			508	11.29	1.36										
4367		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	XBB.1		NT50 GMT			days post booster	0	48			170	3.54	1.00										
4368		10	Beth Israel Deaconess Medical Center, Boston	Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1	https://doi.org/10.1056/NEJMc2214314	Peer-reviewed publication	02/16/2023	human		Mixed	Median of 3 doses of vaccination	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	XBB.1		NT50 GMT			days post booster	0	20			175	8.75	2.47										
4369		11	Moderna	Moderna Annual R&D Day 2022	https://s29.q4cdn.com/435878511/files/doc_presentations/2022/09/Moderna-Final-R-D-Day-Slides_PDF-(09.08.22).pdf	Company presentation	09/08/2022	human	18-64 years of age	Naïve	3 x mRNA-1273	mRNA-1273				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		NT50 GMT			days post booster	0	123	28		422	3.43	1.00										
4370		11	Moderna	Moderna Annual R&D Day 2022	https://s29.q4cdn.com/435878511/files/doc_presentations/2022/09/Moderna-Final-R-D-Day-Slides_PDF-(09.08.22).pdf	Company presentation	09/08/2022	human	18-64 years of age	Naïve	3 x mRNA-1273	mRNA-1273.214				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		NT50 GMT			days post booster	0	105	28		670	6.38	1.86										
4371		11	Moderna	Moderna Annual R&D Day 2022	https://s29.q4cdn.com/435878511/files/doc_presentations/2022/09/Moderna-Final-R-D-Day-Slides_PDF-(09.08.22).pdf	Company presentation	09/08/2022	human	Over 64 years of age	Naïve	3 x mRNA-1273	mRNA-1273				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		NT50 GMT			days post booster	0	161	28		588	3.65	1.00										
4372		11	Moderna	Moderna Annual R&D Day 2022	https://s29.q4cdn.com/435878511/files/doc_presentations/2022/09/Moderna-Final-R-D-Day-Slides_PDF-(09.08.22).pdf	Company presentation	09/08/2022	human	Over 64 years of age	Naïve	3 x mRNA-1273	mRNA-1273.214				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		NT50 GMT			days post booster	0	132	28		817	6.19	1.69										
4373		12	Toyama University Graduate School of Medicine and Pharmaceutical Sciences	Efficacy of the wild-type/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5	https://doi.org/10.1101/2022.11.15.22282328	Pre-print	11/18/2022	human			3 x BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		NT50 GMT	% inhibition		days post booster			14		38.5		1.00										
4374		12	Toyama University Graduate School of Medicine and Pharmaceutical Sciences	Efficacy of the wild-type/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5	https://doi.org/10.1101/2022.11.15.22282328	Pre-print	11/18/2022	human			3 x BNT162b2	mRNA-1273.214/Bivalent BNT162b2 OMI(BA.1)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		NT50 GMT	% inhibition		days post booster			14		68.4		1.78										
4375		12	Toyama University Graduate School of Medicine and Pharmaceutical Sciences	Efficacy of the wild-type/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5	https://doi.org/10.1101/2022.11.15.22282328	Pre-print	11/18/2022	human			3 x BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		NT50 GMT	% inhibition		days post booster			14		10.2		1.00										
4376		12	Toyama University Graduate School of Medicine and Pharmaceutical Sciences	Efficacy of the wild-type/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5	https://doi.org/10.1101/2022.11.15.22282328	Pre-print	11/18/2022	human			3 x BNT162b2	mRNA-1273.214/Bivalent BNT162b2 OMI(BA.1)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		NT50 GMT	% inhibition		days post booster			14		22.7		2.23										
4377		12	Toyama University Graduate School of Medicine and Pharmaceutical Sciences	Efficacy of the wild-type/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5	https://doi.org/10.1101/2022.11.15.22282328	Pre-print	11/18/2022	human			3 x BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	2	Binding	ELISA						Anti-RBD IgG GM	U/mL		days post booster			14		26262		1.00										
4378		12	Toyama University Graduate School of Medicine and Pharmaceutical Sciences	Efficacy of the wild-type/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5	https://doi.org/10.1101/2022.11.15.22282328	Pre-print	11/18/2022	human			3 x BNT162b2	mRNA-1273.214/Bivalent BNT162b2 OMI(BA.1)				None	None	Bivalent	2	Binding	ELISA						Anti-RBD IgG GM	U/mL		days post booster			14		24840		0.95										
4379		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		FFRNT50 GMT			months post booster	0	874	1		2605	2.98	1.00										
4380		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		FFRNT50 GMT			months post booster	0	572	1		3328	5.82	1.95										
4381		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4/5		FFRNT50 GMT			months post booster	0	82	1		236	2.88	1.00										
4382		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4/5		FFRNT50 GMT			months post booster	0	66	1		856	12.97	4.51										
4383		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4.6		FFRNT50 GMT			months post booster	0	81	1		232	2.86	1.00										
4384		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4.6		FFRNT50 GMT			months post booster	0	101	1		905	8.96	3.13										
4385		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.2.75.2		FFRNT50 GMT			months post booster	0	48	1		99	2.06	1.00										
4386		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.2.75.2		FFRNT50 GMT			months post booster	0	29	1		196	6.76	3.28										
4387		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BQ.1.1		FFRNT50 GMT			months post booster	0	31	1		58	1.87	1.00										
4388		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BQ.1.1		FFRNT50 GMT			months post booster	0	29	1		252	8.69	4.64										
4389		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	XBB.1		FFRNT50 GMT			months post booster	0	27	1		41	1.52	1.00										
4390		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Mixed	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	XBB.1		FFRNT50 GMT			months post booster	0	18	1		84	4.67	3.07										
4391		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		FFRNT50 GMT			months post booster	0	304	1		1325	4.36	1.00										
4392		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		FFRNT50 GMT			months post booster	0	226	1		2237	9.90	2.27										
4393		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4/5		FFRNT50 GMT			months post booster	0	30	1		89	2.97	1.00										
4394		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4/5		FFRNT50 GMT			months post booster	0	20	1		518	25.90	8.73										
4395		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4.6		FFRNT50 GMT			months post booster	0	36	1		92	2.56	1.00										
4396		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4.6		FFRNT50 GMT			months post booster	0	24	1		524	21.83	8.54										
4397		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.2.75.2		FFRNT50 GMT			months post booster	0	18	1		37	2.06	1.00										
4398		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.2.75.2		FFRNT50 GMT			months post booster	0	14	1		117	8.36	4.07										
4399		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BQ.1.1		FFRNT50 GMT			months post booster	0	17	1		25	1.47	1.00										
4699																None	None																														
4700																None	None																														
4701																None	None																														
4702																None	None																														
4400		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BQ.1.1		FFRNT50 GMT			months post booster	0	11	1		143	13.00	8.84										
4401		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	XBB.1		FFRNT50 GMT			months post booster	0	13	1		17	1.31	1.00										
4402		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Naïve	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	XBB.1		FFRNT50 GMT			months post booster	0	12	1		55	4.58	3.50										
4403		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		FFRNT50 GMT			months post booster	0	2516	1		5120	2.03	1.00										
4404		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		FFRNT50 GMT			months post booster	0	1377	1		4847	3.52	1.73										
4405		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4/5		FFRNT50 GMT			months post booster	0	226	1		629	2.78	1.00										
4406		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4/5		FFRNT50 GMT			months post booster	0	207	1		1377	6.65	2.39										
4407		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4.6		FFRNT50 GMT			months post booster	0	283	1		587	2.07	1.00										
4408		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.4.6		FFRNT50 GMT			months post booster	0	282	1		1564	5.55	2.67										
4409		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.2.75.2		FFRNT50 GMT			months post booster	0	126	1		264	2.10	1.00										
4410		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BA.2.75.2		FFRNT50 GMT			months post booster	0	62	1		326	5.26	2.51										
4411		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BQ.1.1		FFRNT50 GMT			months post booster	0	60	1		132	2.20	1.00										
4412		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	BQ.1.1		FFRNT50 GMT			months post booster	0	74	1		444	6.00	2.73										
4413		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	BNT162b2	30	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	XBB.1		FFRNT50 GMT			months post booster	0	55	1		98	1.78	1.00										
4414		13	University of Texas Medical Branch	Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine	https://doi.org/10.1101/2022.11.17.516898	Pre-print	11/17/2022	human	Over 55 years of age	Infected	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)	30	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	XBB.1		FFRNT50 GMT			months post booster	0	27	1		131	4.85	2.72										
4415		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Mixed	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	205	28		643	3.14	1.00										
4416		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Mixed	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	284	28		4289	15.10	4.81										
4417		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	136	28		489	3.60	1.00										
4418		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	88	28		2325	26.42	7.35										
4419		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	617	28		1280	2.07	1.00										
4420		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	710	28		6965	9.81	4.73										
4421		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Mixed	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	1941	28		6050	3.12	1.00										
4422		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Mixed	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	1620	28		9319	5.75	1.85										
4423		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	1515	28		5651	3.73	1.00										
4424		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	797	28		7322	9.19	2.46										
4425		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	3650	28		6979	1.91	1.00										
4426		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	2841	28		11198	3.94	2.06										
4427		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	MSD assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Anti-spike IgG GM			days post booster	0	279483.7	28		796220.3	2.85	1.00										
4428		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	2	Binding	MSD assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Anti-spike IgG GM			days post booster	0	120499.9	28		845092.4	7.01	2.46										
4429		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	MSD assay		Omicron	B.1.1.529	BA.1		Anti-spike IgG GM			days post booster	0	56564.1	28		177980.6	3.15	1.00										
4430		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	2	Binding	MSD assay		Omicron	B.1.1.529	BA.1		Anti-spike IgG GM			days post booster	0	25609.7	28		228114	8.91	2.83										
4431		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	MSD assay		alpha	B.1.1.7	B.1.1.7		Anti-spike IgG GM			days post booster	0	206919.5	28		598907.1	2.89	1.00										
4432		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	2	Binding	MSD assay		alpha	B.1.1.7	B.1.1.7		Anti-spike IgG GM			days post booster	0	93589.5	28		665136.7	7.11	2.46										
4433		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	MSD assay		gamma	P.1	P.1		Anti-spike IgG GM			days post booster	0	135931.8	28		396861.4	2.92	1.00										
4434		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	2	Binding	MSD assay		gamma	P.1	P.1		Anti-spike IgG GM			days post booster	0	63411.1	28		516162.8	8.14	2.79										
4435		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	MSD assay		delta	B.1.617.2	B.1.617.2		Anti-spike IgG GM			days post booster	0	175659.4	28		519695.1	2.96	1.00										
4436		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	2	Binding	MSD assay		delta	B.1.617.2	B.1.617.2		Anti-spike IgG GM			days post booster	0	90420	28		652079.7	7.21	2.44										
4703																None	None																														
4437		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	MSD assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Anti-spike IgG GM			days post booster	0	358525.8	28		695725.8	1.94	1.00										
4438		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	2	Binding	MSD assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Anti-spike IgG GM			days post booster	0	258113.8	28		857657.7	3.32	1.71										
4439		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	MSD assay		Omicron	B.1.1.529	BA.1		Anti-spike IgG GM			days post booster	0	69048.6	28		148377.3	2.15	1.00										
4440		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	2	Binding	MSD assay		Omicron	B.1.1.529	BA.1		Anti-spike IgG GM			days post booster	0	52662.3	28		223117.3	4.24	1.97										
4441		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	MSD assay		alpha	B.1.1.7	B.1.1.7		Anti-spike IgG GM			days post booster	0	281608	28		549296.6	1.95	1.00										
4442		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	2	Binding	MSD assay		alpha	B.1.1.7	B.1.1.7		Anti-spike IgG GM			days post booster	0	214881.7	28		708888.9	3.30	1.69										
4443		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	MSD assay		gamma	P.1	P.1		Anti-spike IgG GM			days post booster	0	196151.1	28		396864.7	2.02	1.00										
4444		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	2	Binding	MSD assay		gamma	P.1	P.1		Anti-spike IgG GM			days post booster	0	155707.8	28		595259.4	3.82	1.89										
4445		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	MSD assay		delta	B.1.617.2	B.1.617.2		Anti-spike IgG GM			days post booster	0	255142.6	28		505719.7	1.98	1.00										
4446		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	2	Binding	MSD assay		delta	B.1.617.2	B.1.617.2		Anti-spike IgG GM			days post booster	0	205035.6	28		706974.9	3.45	1.74										
4447		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	121.8	28		602.1	4.94	1.00										
4448		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	122.8	28		3355.4	27.32	5.53										
4449		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	1067.6	28		3116.8	2.92	1.00										
4450		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster	0	833.7	28		8871.8	10.64	3.65										
4451		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BQ.1.1		ID50 GMT			days post booster	0	39.2	28		161.1	4.11	1.00										
4452		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BQ.1.1		ID50 GMT			days post booster	0	31.7	28		621.9	19.62	4.77										
4453		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BQ.1.1		ID50 GMT			days post booster	0	147.8	28		475.5	3.22	1.00										
4454		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BQ.1.1		ID50 GMT			days post booster	0	124.7	28		1093.5	8.77	2.73										
4455		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	XBB.1		ID50 GMT			days post booster	0	14.4	28		50.6	3.51	1.00										
4456		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Naïve	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	XBB.1		ID50 GMT			days post booster	0	18.1	28		222.3	12.28	3.50										
4704																None	None																														
4705																None	None																														
4457		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273	50	?g		None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	XBB.1		ID50 GMT			days post booster	0	75.1	28		214.2	2.85	1.00										
4458		14	Moderna	Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19	https://doi.org/10.1101/2022.12.11.22283166	Pre-print	12/13/2022	human		Infected	3 x mRNA-1273	mRNA-1273.222	50	?g		None	None	Bivalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	XBB.1		ID50 GMT			days post booster	0	55.4	28		381.4	6.88	2.41										
4459		15	Medigen Vaccine Biologics Corporation	Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants	https://doi.org/10.1101/2022.10.07.511263	Pre-print	10/07/2022	mice		Naïve	2 x S-2P(WT)	MVC-COV1901	3	mcg		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		ID90 GMT			days post booster			14		5274		1.00										
4460		15	Medigen Vaccine Biologics Corporation	Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants	https://doi.org/10.1101/2022.10.07.511263	Pre-print	10/07/2022	mice		Naïve	2 x S-2P(WT)	MVC-COV1901 (Ancestral+BA.1)	3	mcg		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		ID90 GMT			days post booster			14														
4461		15	Medigen Vaccine Biologics Corporation	Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants	https://doi.org/10.1101/2022.10.07.511263	Pre-print	10/07/2022	mice		Naïve	2 x S-2P(WT)	MVC-COV1901 (Ancestral+BA.4/5)	3	mcg		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		ID90 GMT			days post booster			14		8946		1.70										
4462		15	Medigen Vaccine Biologics Corporation	Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants	https://doi.org/10.1101/2022.10.07.511263	Pre-print	10/07/2022	mice		Naïve	2 x S-2P(WT)	MVC-COV1901	3	mcg		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID90 GMT			days post booster			14		64.6		1.00										
4463		15	Medigen Vaccine Biologics Corporation	Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants	https://doi.org/10.1101/2022.10.07.511263	Pre-print	10/07/2022	mice		Naïve	2 x S-2P(WT)	MVC-COV1901 (Ancestral+BA.1)	3	mcg		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID90 GMT			days post booster			14		186.3		2.88										
4464		15	Medigen Vaccine Biologics Corporation	Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants	https://doi.org/10.1101/2022.10.07.511263	Pre-print	10/07/2022	mice		Naïve	2 x S-2P(WT)	MVC-COV1901 (Ancestral+BA.4/5)	3	mcg		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID90 GMT			days post booster			14		1473		22.80										
4465		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	518.1	28		2911.3	5.62	1.00										
4466		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	501.6	28		2987.2	5.96	1.06										
4467		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	52.1	28		311.8	5.98	1.00										
4468		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	50.9	28		466.8	9.17	1.53										
4469		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Infected	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	2858.6	28		6546.9	2.29	1.00										
4470		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Infected	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	2884.7	28		8067.2	2.80	1.22										
4471		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Infected	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	335.8	28		905.8	2.70	1.00										
4472		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Infected	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	345.4	28		1722.5	4.99	1.85										
4473		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Mixed	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	796.4	28		3716.6	4.67	1.00										
4706																None	None																														
4707																None	None																														
4708																None	None																														
4474		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Mixed	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	735.8	28		3811.1	5.18	1.11										
4475		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Mixed	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	84	28		431.6	5.14	1.00										
4476		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Mixed	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	77.7	28		644.2	8.29	1.61										
4477		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Anti-spike IgG GMC	AU/mL		days post booster	0	56446	28		289679	5.13	1.00										
4478		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Anti-spike IgG GMC	AU/mL		days post booster	0	55263	28		297748	5.39	1.05										
4479		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		Omicron	B.1.1.529	BA.1		Anti-spike IgG GMC	AU/mL		days post booster	0	11986	28		75188	6.27	1.00										
4480		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		Omicron	B.1.1.529	BA.1		Anti-spike IgG GMC	AU/mL		days post booster	0	11758	28		84037	7.15	1.14										
4481		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		alpha	B.1.1.7	B.1.1.7		Anti-spike IgG GMC	AU/mL		days post booster	0	41471	28		223994	5.40	1.00										
4482		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		alpha	B.1.1.7	B.1.1.7		Anti-spike IgG GMC	AU/mL		days post booster	0	40410	28		236132	5.84	1.08										
4483		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		delta	B.1.617.2	B.1.617.2		Anti-spike IgG GMC	AU/mL		days post booster	0	42819	28		234006	5.47	1.00										
4484		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		delta	B.1.617.2	B.1.617.2		Anti-spike IgG GMC	AU/mL		days post booster	0	41553	28		244278	5.88	1.08										
4485		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273	50	?g		None	None	Monovalent	2	Binding	Meso Scale Discovery assay		gamma	P.1	P.1		Anti-spike IgG GMC	AU/mL		days post booster	0	33582	28		173773	5.17	1.00										
4486		16	Moderna	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	https://doi.org/10.1101/2023.01.24.23284869	Pre-print	01/24/2023	human		Naïve	Mixed regimen	mRNA-1273.214	50	?g		None	None	Bivalent	2	Binding	Meso Scale Discovery assay		gamma	P.1	P.1		Anti-spike IgG GMC	AU/mL		days post booster	0	32757	28		182119	5.56	1.07										
4487		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	BNT162b2				None	None	Monovalent	1	Binding	Flow cytometry	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Median Fluorescence intensities (MFI)			days post booster			28		126		1.00										
4488		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Binding	Flow cytometry	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Median Fluorescence intensities (MFI)			days post booster			28		114		0.90										
4489		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	BNT162b2				None	None	Monovalent	1	Binding	Flow cytometry	Fluorescence	Omicron	B.1.1.529	BA.1		Median Fluorescence intensities (MFI)			days post booster			28		27		1.00										
4490		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Binding	Flow cytometry	Fluorescence	Omicron	B.1.1.529	BA.1		Median Fluorescence intensities (MFI)			days post booster			28		18		0.67										
4491		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	mRNA-1273				None	None	Monovalent	1	Binding	Flow cytometry	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Median Fluorescence intensities (MFI)			days post booster			28		128		1.00										
4709																None	None																														
4710																None	None																														
4711																None	None																														
4492		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	mRNA-1273.214				None	None	Bivalent	1	Binding	Flow cytometry	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Median Fluorescence intensities (MFI)			days post booster			28		227		1.77										
4493		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	mRNA-1273				None	None	Monovalent	1	Binding	Flow cytometry	Fluorescence	Omicron	B.1.1.529	BA.1		Median Fluorescence intensities (MFI)			days post booster			28		31		1.00										
4494		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	mRNA-1273.214				None	None	Bivalent	1	Binding	Flow cytometry	Fluorescence	Omicron	B.1.1.529	BA.1		Median Fluorescence intensities (MFI)			days post booster			28		61		1.97										
4495		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	BNT162b2				None	None	Monovalent	1	Binding	Flow cytometry	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Median Fluorescence intensities (MFI)			days post booster			28		104		1.00										
4496		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Binding	Flow cytometry	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Median Fluorescence intensities (MFI)			days post booster			28		140		1.35										
4497		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	BNT162b2				None	None	Monovalent	1	Binding	Flow cytometry	Fluorescence	Omicron	B.1.1.529	BA.1		Median Fluorescence intensities (MFI)			days post booster			28		44		1.00										
4498		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Binding	Flow cytometry	Fluorescence	Omicron	B.1.1.529	BA.1		Median Fluorescence intensities (MFI)			days post booster			28		38		0.86										
4499		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	mRNA-1273				None	None	Monovalent	1	Binding	Flow cytometry	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Median Fluorescence intensities (MFI)			days post booster			28		161		1.00										
4500		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	mRNA-1273.214				None	None	Bivalent	1	Binding	Flow cytometry	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Median Fluorescence intensities (MFI)			days post booster			28		256		1.59										
4501		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	mRNA-1273				None	None	Monovalent	1	Binding	Flow cytometry	Fluorescence	Omicron	B.1.1.529	BA.1		Median Fluorescence intensities (MFI)			days post booster			28		52		1.00										
4502		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	mRNA-1273.214				None	None	Bivalent	1	Binding	Flow cytometry	Fluorescence	Omicron	B.1.1.529	BA.1		Median Fluorescence intensities (MFI)			days post booster			28		71		1.37										
4503		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	BNT162b2				None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster			28		995		1.00										
4504		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster			28		903		0.91										
4505		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	BNT162b2				None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster			28		160		1.00										
4506		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster			28		50		0.31										
4507		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	mRNA-1273				None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster			28		1237		1.00										
4508		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	mRNA-1273.214				None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster			28		5142		4.16										
4509		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	mRNA-1273				None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster			28		114		1.00										
4712																None	None																														
4510		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Naïve	3 x BNT162b2	mRNA-1273.214				None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster			28		521		4.57										
4511		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	BNT162b2				None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster			28		3576		1.00										
4512		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster			28		2310		0.65										
4513		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	BNT162b2				None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster			28		376		1.00										
4514		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster			28		326		0.87										
4515		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	mRNA-1273				None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster			28		5411		1.00										
4516		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	mRNA-1273.214				None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster			28		4460		0.82										
4517		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	mRNA-1273				None	None	Monovalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster			28		405		1.00										
4518		17	Université de Montréal	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/20/2022	human		Infected	3 x BNT162b2	mRNA-1273.214				None	None	Bivalent	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster			28		1356		3.35										
4519		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	BNT162b2	CoV2 preS dTM-AS03 (D614G)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	339	15		7894	23.29	1.00										
4520		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	BNT162b2	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	585	15		8550	14.62	0.63										
4521		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	mRNA-1273	CoV2 preS dTM-AS03 (D614G)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	808	15		6958	8.61	1.00										
4522		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	mRNA-1273	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	1400	15		12496	8.93	1.04										
4523		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	ChAd	CoV2 preS dTM-AS03 (D614G)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	249	15		6663	26.76	1.00										
4524		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	ChAd	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	138	15		6923	50.17	1.87										
4525		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	Ad26	CoV2 preS dTM-AS03 (D614G)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	510	15		7204	14.13	1.00										
4526		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	Ad26	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster	0	510	15		9160	17.96	1.27										
4713																None	None																														
4527		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	BNT162b2	CoV2 preS dTM-AS03 (B.1.315)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	200	15		7172	35.86	1.00										
4528		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	BNT162b2	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	151	15		5087	33.69	0.94										
4529		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	mRNA-1273	CoV2 preS dTM-AS03 (B.1.315)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	296	15		9146	30.90	1.00										
4530		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	mRNA-1273	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	300	15		6698	22.33	0.72										
4531		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	ChAd	CoV2 preS dTM-AS03 (B.1.315)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	50	15		5643	112.86	1.00										
4532		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	ChAd	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	39	15		4056	104.00	0.92										
4533		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	Ad26	CoV2 preS dTM-AS03 (B.1.315)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	306	15		7900	25.82	1.00										
4534		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human		Mixed	Ad26	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster	0	136	15		3951	29.05	1.13										
4535		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human	18-55 years of age	Mixed	Authorized vaccines	CoV2 preS dTM-AS03 (D614G)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		ID50 GMT			days post booster	0	38	15		953	25.08	1.00										
4536		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human	18-55 years of age	Mixed	Authorized vaccines	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		ID50 GMT			days post booster	0	77	15		1810	23.51	0.94										
4537		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human	Over 56 years of age	Mixed	Authorized vaccines	CoV2 preS dTM-AS03 (D614G)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		ID50 GMT			days post booster	0	28	15		775	27.68	1.00										
4538		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human	Over 56 years of age	Mixed	Authorized vaccines	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		ID50 GMT			days post booster	0	64	15		1277	19.95	0.72										
4539		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human	18-55 years of age	Mixed	Authorized vaccines	CoV2 preS dTM-AS03 (D614G)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	22	15		819	37.23	1.00										
4540		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human	18-55 years of age	Mixed	Authorized vaccines	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	38	15		1450	38.16	1.02										
4541		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human	Over 56 years of age	Mixed	Authorized vaccines	CoV2 preS dTM-AS03 (D614G)				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	34	15		364	10.71	1.00										
4542		18	Sanofi	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines	https://doi.org/10.1101/2022.12.20.22283723	Pre-print	12/03/2022	human	Over 56 years of age	Mixed	Authorized vaccines	Bivalent CoV2 preS dTM-AS03 (D614+B.1.351)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	63	15		1453	23.06	2.15										
4543		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			months post booster			1		15642		1.00										
4544		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			months post booster			1		12805		0.82										
4545		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		ID50 GMT			months post booster			1		2049		1.00										
4546		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		ID50 GMT			months post booster			1		2612		1.27										
4547		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		ID50 GMT			months post booster			1		1218		1.00										
4548		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		ID50 GMT			months post booster			1		1553		1.28										
4549		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BQ.1.1		ID50 GMT			months post booster			1		310		1.00										
4550		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BQ.1.1		ID50 GMT			months post booster			1		356		1.15										
4551		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	XBB.1.5		ID50 GMT			months post booster			1		116		1.00										
4552		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	XBB.1.5		ID50 GMT			months post booster			1		152		1.31										
4553		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			months post booster			3		6601		1.00										
4554		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			months post booster			3		6438		0.98										
4555		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		ID50 GMT			months post booster			3		924		1.00										
4556		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		ID50 GMT			months post booster			3		1322		1.43										
4557		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		ID50 GMT			months post booster			3		509		1.00										
4558		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.5		ID50 GMT			months post booster			3		835		1.64										
4559		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BQ.1.1		ID50 GMT			months post booster			3		129		1.00										
4714																None	None																														
4715																None	None																														
4560		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BQ.1.1		ID50 GMT			months post booster			3		182		1.41										
4561		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273/BNT162b2				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	XBB.1.5		ID50 GMT			months post booster			3		50		1.00										
4562		19	Columbia University Vagelos College of Physicians and Surgeons	SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster	https://doi.org/10.1101/2023.02.13.528341	Pre-print	02/14/2023	human		Naïve	3 x mRNA-1273/BNT162b2	mRNA-1273.222/Bivalent BNT162b2 OMI(BA.4/5)				None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	XBB.1.5		ID50 GMT			months post booster			3		74		1.48										
4563		20	University of Tehran	Omicron-Specific and Bivalent Omicron-Containing Vaccine Candidates Elicit Potent Virus Neutralisation in the Animal Model	https://doi.org/10.1101/2022.02.11.480131	Pre-print	02/20/2023	rat			BIV1-CovIran	BIV1-CovIran				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	TCID50 GMT			days post booster			28		388		1.00										
4564		20	University of Tehran	Omicron-Specific and Bivalent Omicron-Containing Vaccine Candidates Elicit Potent Virus Neutralisation in the Animal Model	https://doi.org/10.1101/2022.02.11.480131	Pre-print	02/20/2023	rat			2 x BBIV1-CovIran	BBIV1-CovIran	2.5+2.5	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	TCID50 GMT			days post booster			28		222.9		0.57										
4565		20	University of Tehran	Omicron-Specific and Bivalent Omicron-Containing Vaccine Candidates Elicit Potent Virus Neutralisation in the Animal Model	https://doi.org/10.1101/2022.02.11.480131	Pre-print	02/20/2023	rat			2 x BBIV1-CovIran	BBIV1-CovIran	5+5	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	TCID50 GMT			days post booster			28		445.7		1.15										
4566		20	University of Tehran	Omicron-Specific and Bivalent Omicron-Containing Vaccine Candidates Elicit Potent Virus Neutralisation in the Animal Model	https://doi.org/10.1101/2022.02.11.480131	Pre-print	02/20/2023	rat			BIV1-CovIran	BIV1-CovIran				None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		TCID50 GMT			days post booster			28		27.9		1.00										
4567		20	University of Tehran	Omicron-Specific and Bivalent Omicron-Containing Vaccine Candidates Elicit Potent Virus Neutralisation in the Animal Model	https://doi.org/10.1101/2022.02.11.480131	Pre-print	02/20/2023	rat			2 x BBIV1-CovIran	BBIV1-CovIran	2.5+2.5	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		TCID50 GMT			days post booster			28		222.9		7.99										
4568		20	University of Tehran	Omicron-Specific and Bivalent Omicron-Containing Vaccine Candidates Elicit Potent Virus Neutralisation in the Animal Model	https://doi.org/10.1101/2022.02.11.480131	Pre-print	02/20/2023	rat			2 x BBIV1-CovIran	BBIV1-CovIran	5+5	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		TCID50 GMT			days post booster			28		388		13.91										
4569		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	SCB-2019	3	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		IC50 GMT			days post booster			28		16101		1.00	57		13559		1.00			15982		1.00
4570		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	Bivalent SCB-2019+SCB-2022B	1.5+1.5	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		IC50 GMT			days post booster			28		15407		0.96	57		16230		1.20			19525		1.22
4571		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	SCB-2019	3	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	alpha	B.1.1.7	B.1.1.7		IC50 GMT			days post booster			28		13396		1.00	57		8168		1.00			9177		1.00
4572		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	Bivalent SCB-2019+SCB-2022B	1.5+1.5	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	alpha	B.1.1.7	B.1.1.7		IC50 GMT			days post booster			28		22604		1.69	57		11756		1.44			13356		1.46
4573		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	SCB-2019	3	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		IC50 GMT			days post booster			28		18130		1.00	57		3498		1.00			4416		1.00
4574		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	Bivalent SCB-2019+SCB-2022B	1.5+1.5	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		IC50 GMT			days post booster			28		15716		0.87	57		4482		1.28			9113		2.06
4575		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	SCB-2019	3	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		IC50 GMT			days post booster			28		26427		1.00	57		13288		1.00			25355		1.00
4576		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	Bivalent SCB-2019+SCB-2022B	1.5+1.5	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		IC50 GMT			days post booster			28		24509		0.93	57		12403		0.93			33037		1.30
4577		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	SCB-2019	3	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	gamma	P.1	P.1		IC50 GMT			days post booster			28		6241		1.00	57		9879		1.00			5768		1.00
4716																None	None																														
4717																None	None																														
4578		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	Bivalent SCB-2019+SCB-2022B	1.5+1.5	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	gamma	P.1	P.1		IC50 GMT			days post booster			28		9757		1.56	57		9162		0.93			5961		1.03
4579		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	SCB-2019	3	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		IC50 GMT			days post booster			28		500		1.00	57		213		1.00			202		1.00
4580		21	Clover Biopharmaceuticals	Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine	https://doi.org/10.1101/2022.05.03.490428	Pre-print	05/03/2022	mice		Naïve	SCB-2019	Bivalent SCB-2019+SCB-2022B	1.5+1.5	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		IC50 GMT			days post booster			28		2305		4.61	57		716		3.36			799		3.96
4581		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Mixed	none	mRNA-1273	25	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		nAb GMC			days post booster	1	5.9	28		74.3	12.59	1.00										
4582		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Mixed	none	mRNA-1273.214	25	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		nAb GMC			days post booster	1	49.2	28		1889.7	38.41	3.05										
4583		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Mixed	none	mRNA-1273	25	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	nAb GMC			days post booster	1	9.6	28		1732.5	180.47	1.00										
4584		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Mixed	none	mRNA-1273.214	25	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	nAb GMC			days post booster	1	35.6	28		1432.9	40.25	0.22										
4585		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Naïve	none	mRNA-1273	25	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		nAb GMC			days post booster	1	5.4	28		65.7	12.17	1.00										
4586		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Naïve	none	mRNA-1273.214	25	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		nAb GMC			days post booster	1	8.1	28		1037.9	128.14	10.53										
4587		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Naïve	none	mRNA-1273	25	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	nAb GMC			days post booster	1	7.7	28		1559.4	202.52	1.00										
4588		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Naïve	none	mRNA-1273.214	25	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	nAb GMC			days post booster	1	12.5	28		612.5	49.00	0.24										
4589		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Infected	none	mRNA-1273	25	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		nAb GMC			days post booster	1	21.6	28		625.3	28.95	1.00										
4590		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Infected	none	mRNA-1273.214	25	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		nAb GMC			days post booster	1	137.2	28		2884.6	21.02	0.73										
4591		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Infected	none	mRNA-1273	25	?g		None	None	Monovalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	nAb GMC			days post booster	1	185.8	28		8445.1	45.45	1.00										
4592		22	Moderna	Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children	https://doi.org/10.1101/2023.06.23.23291767	Pre-print	06/29/2023	human	6 months to 5 years old	Infected	none	mRNA-1273.214	25	?g		None	None	Bivalent	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	nAb GMC			days post booster	1	65.4	28		2405.9	36.79	0.81										
4593		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster	0	486.7	14		1442.5	2.96	1.00	28		1442.8	2.96	1.00					
4594		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster	0	457.6	14		1076.3	2.35	0.79	28		860.8	1.88	0.63					
4718																None	None																														
4719																None	None																														
4720																None	None																														
4721																None	None																														
4722																None	None																														
4595		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster	0	431.1	14		1319.9	3.06	1.03	28		1087.4	2.52	0.85					
4596		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		MN50 GMT			days post booster	0	27.9	14		83.9	3.01	1.00	28		77.5	2.78	1.00					
4597		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		MN50 GMT			days post booster	0	25.2	14		130.8	5.19	1.73	28		122.3	4.85	1.75					
4598		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		MN50 GMT			days post booster	0	26	14		97.9	3.77	1.25	28		87.4	3.36	1.21					
4599		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	2	Binding	ELISA		Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		Anti-S IgG GMC	EU/mL		days post booster	0	20168.6	14		53531.1	2.65	1.00	28		54598.2	2.71	1.00					
4600		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	2	Binding	ELISA		Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		Anti-S IgG GMC	EU/mL		days post booster	0	18773.6	14		40423.4	2.15	0.81	28		40833.4	2.18	0.80					
4601		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	2	Binding	ELISA		Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		Anti-S IgG GMC	EU/mL		days post booster	0	17803.1	14		42783.9	2.40	0.91	28		41070	2.31	0.85					
4602		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	2	Binding	ELISA		Omicron	B.1.1.529	BA.1		Anti-S IgG GMC	EU/mL		days post booster	0	9770.2	14		30170.9	3.09	1.00	28		28448.6	2.91	1.00					
4603		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	2	Binding	ELISA		Omicron	B.1.1.529	BA.1		Anti-S IgG GMC	EU/mL		days post booster	0	9117.3	14		24174.8	2.65	0.86	28		22732.1	2.49	0.86					
4604		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	2	Binding	ELISA		Omicron	B.1.1.529	BA.1		Anti-S IgG GMC	EU/mL		days post booster	0	8598.7	14		23045.5	2.68	0.87	28		21772.1	2.53	0.87					
4605		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		ID50 GMT			days post booster	0	517.1	14		1473	2.85	1.00	28		1420.2	2.75	1.00					
4606		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		ID50 GMT			days post booster	0	496.7	14		1181.1	2.38	0.83	28		1085.8	2.19	0.80					
4607		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		ID50 GMT			days post booster	0	483.3	14		1195.1	2.47	0.87	28		1106.1	2.29	0.83					
4608		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	103.6	14		449.1	4.33	1.00	28		404.1	3.90	1.00					
4609		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	99.6	14		816.1	8.19	1.89	28		661.6	6.64	1.70					
4723																None	None																														
4724																None	None																														
4610		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Naïve	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	89.2	14		562	6.30	1.45	28		502.1	5.63	1.44					
4611		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster	0	1280	14		2702	2.11	1.00	28		2456	1.92	1.00					
4612		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster	0	1151.3	14		2206.2	1.92	0.91	28		1918.8	1.67	0.87					
4613		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster	0	1232	14		2544.7	2.07	0.98	28		2144	1.74	0.91					
4614		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		MN50 GMT			days post booster	0	105.9	14		218.1	2.06	1.00	28		195.7	1.85	1.00					
4615		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		MN50 GMT			days post booster	0	97.3	14		318.2	3.27	1.59	28		284.8	2.93	1.58					
4616		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		MN50 GMT			days post booster	0	106.1	14		252.7	2.38	1.16	28		218.7	2.06	1.12					
4617		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	2	Binding	ELISA		Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		Anti-S IgG GMC	EU/mL		days post booster	0	47810.6	14		90962.2	1.90	1.00	28		87969.9	1.84	1.00					
4618		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	2	Binding	ELISA		Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		Anti-S IgG GMC	EU/mL		days post booster	0	44166.7	14		71076.4	1.61	0.85	28		70523.9	1.60	0.87					
4619		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	2	Binding	ELISA		Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		Anti-S IgG GMC	EU/mL		days post booster	0	45047.6	14		78191.9	1.74	0.91	28		73321.3	1.63	0.88					
4620		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	2	Binding	ELISA		Omicron	B.1.1.529	BA.1		Anti-S IgG GMC	EU/mL		days post booster	0	9770.2	14		49727.7	5.09	1.00	28		44756.4	4.58	1.00					
4621		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	2	Binding	ELISA		Omicron	B.1.1.529	BA.1		Anti-S IgG GMC	EU/mL		days post booster	0	9117.3	14		42835.5	4.70	0.92	28		40044.9	4.39	0.96					
4622		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	2	Binding	ELISA		Omicron	B.1.1.529	BA.1		Anti-S IgG GMC	EU/mL		days post booster	0	8598.7	14		42462.1	4.94	0.97	28		38315.6	4.46	0.97					
4623		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		ID50 GMT			days post booster	0	1646.5	14		3027.9	1.84	1.00	28		2716.9	1.65	1.00					
4624		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		ID50 GMT			days post booster	0	1491.2	14		2514.9	1.69	0.92	28		2411.6	1.62	0.98					
4725																None	None																														
4726																None	None																														
4625		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		ID50 GMT			days post booster	0	1476.4	14		2390.1	1.62	0.88	28		2236	1.51	0.92					
4626		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2373				None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	579.2	14		1390.3	2.40	1.00	28		1195.7	2.06	1.00					
4627		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	NVX-CoV-2515				None	None	Monovalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	548.4	14		2071.5	3.78	1.57	28		1918	3.50	1.69					
4628		23	Novavax	Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial	https://doi.org/10.1101/2023.07.05.23291954	Pre-print	07/06/2023	human	18-64 years of age	Mixed	3 x mRNA-1273/BNT162b2	Bivalent NVX-CoV-2373+NVX-CoV-2515				None	None	Bivalent	3	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster	0	491.9	14		1480.4	3.01	1.25	28		1272.4	2.59	1.25					